FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)

View source ↗

Summary

The FDA approves a supplemental NDA for the methylphenidate transdermal system (patch) from Padagis US LLC, expanding the product’s approved use/label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate Transdermal System (methylphenidate)

Snippet

SUPPL AP for METHYLPHENIDATE TRANSDERMAL SYSTEM (METHYLPHENIDATE)